Company Filing History:
17 out of 30 
8 out of 20 Years Active: 2022-2025
Title: Dajun Yang: Innovator in Cancer Treatment
Introduction
Dajun Yang is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of cancer treatment. With a total of 17 patents to his name, Yang has focused on developing innovative therapies that target hematological malignancies.
Latest Patents
Among his latest patents is a combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent. This invention provides a method for the prevention and treatment of diseases, particularly cancer. The combination product includes a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof. This combination is designed for the preparation of a medicament aimed at treating hematological malignancies. Another notable patent involves N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors, which outlines methods for treating hematologic malignancies through a step-wise dosing regimen.
Career Highlights
Dajun Yang has made significant strides in his career, particularly through his work with Ascentage Pharma, a leading biopharmaceutical company. His role at Ascentage Pharma (Suzhou) Co., Ltd. and Ascentage Pharma Group Corp Limited has allowed him to contribute to groundbreaking research and development in cancer therapies.
Collaborations
Yang has collaborated with notable colleagues in the field, including Yifan Zhai and Douglas Dong Fang. These partnerships have further enhanced his research and innovation efforts.
Conclusion
Dajun Yang's work exemplifies the impact of innovative thinking in the medical field, particularly in the fight against cancer. His patents and collaborations reflect a commitment to advancing treatment options for patients in need.